DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their price objective on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating for the company in a report on Tuesday, September 11th. Stifel Nicolaus assumed coverage on DBV TECHNOLOGIE/S in a report on Thursday, September 13th. They issued a “buy” rating and a $35.00 price objective for the company. BidaskClub upgraded DBV TECHNOLOGIE/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 19th. Finally, Bank of America reduced their price objective on DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $33.67.
Shares of DBVT traded down $0.59 during trading hours on Wednesday, hitting $14.57. The company had a trading volume of 57,443 shares, compared to its average volume of 127,042. The firm has a market cap of $861.24 million, a PE ratio of -4.32 and a beta of 1.18. DBV TECHNOLOGIE/S has a 52-week low of $14.57 and a 52-week high of $26.98.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd bought a new stake in DBV TECHNOLOGIE/S in the 2nd quarter worth about $285,000. Exane Asset Management grew its stake in shares of DBV TECHNOLOGIE/S by 17.9% during the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after purchasing an additional 7,600 shares during the period. Bailard Inc. grew its stake in shares of DBV TECHNOLOGIE/S by 57.4% during the 3rd quarter. Bailard Inc. now owns 74,000 shares of the company’s stock valued at $1,662,000 after purchasing an additional 27,000 shares during the period. First Midwest Bank Trust Division grew its stake in shares of DBV TECHNOLOGIE/S by 19.3% during the 3rd quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock valued at $3,669,000 after purchasing an additional 26,372 shares during the period. Finally, BlackRock Inc. grew its stake in shares of DBV TECHNOLOGIE/S by 4.7% during the 2nd quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares during the period. Institutional investors own 45.43% of the company’s stock.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: What are defining characteristics of a correction?
Get a free copy of the Zacks research report on DBV TECHNOLOGIE/S (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.